GMAB.DK

1,719

+0.7%↑

COLO.B.DK

451.6

+0.92%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

GMAB.DK

1,719

+0.7%↑

COLO.B.DK

451.6

+0.92%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

GMAB.DK

1,719

+0.7%↑

COLO.B.DK

451.6

+0.92%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

GMAB.DK

1,719

+0.7%↑

COLO.B.DK

451.6

+0.92%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

GMAB.DK

1,719

+0.7%↑

COLO.B.DK

451.6

+0.92%↑

HLUNB.DK

37.64

+0.75%↑

AMBUB.DK

71.85

-0.14%↓

ZEAL.DK

280.9

+4.19%↑

Inicio・Lista de Acciones・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Cerrado

247.5 0.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

245.7

Máximo

248.25

Métricas clave
By Trading Economics
Ingresos	6.9B 27B
Ventas	4.2B 79B
P/B Media del Sector	11.051 61.417
BPA	6.04
Rentabilidad por dividendo	4.72
Margen de beneficio	33.977
Empleados	68,794
EBITDA	3.5B 37B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+9.53% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	4.72% 2.40%
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-528B 1.1T
Apertura anterior	247.28
Cierre anterior	247.5

Novo Nordisk A-S (Class B) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 mar 2026, 10:13 UTC

Principales Movimientos del Mercado

Hims & Hers Shares Double on Report of Wegovy Tie-Up

2 mar 2026, 10:04 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Invest $510 Million in Boosting Irish Manufacturing Capacity

23 feb 2026, 11:08 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Rival in Trial -- Update

23 feb 2026, 10:09 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Slide After Obesity Drug Misses Key Goal in Trial

9 feb 2026, 09:37 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Jump After Hims & Hers Scraps Plan For Copycat Weight-Loss Pill

10 mar 2026, 11:06 UTC

Noticias de Eventos Importantes

Trump Soothes Market's Iran Fears. Why the -2-

10 mar 2026, 11:06 UTC

Noticias de Eventos Importantes

Trump Soothes Market's Iran Fears. Why the Threat's Not Over for Stocks, Oil. -- Barrons.com

9 mar 2026, 13:37 UTC

Charlas de Mercado

Hims, Novo Nordisk Bound by Mutual Necessity -- Market Talk

9 mar 2026, 12:49 UTC

Charlas de Mercado

Hims Could See Near-Term Headwinds From Novo Partnership -- Market Talk

24 feb 2026, 21:44 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More -- Barrons.com

24 feb 2026, 19:57 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, IBM, Kratos, Vir Biotechnology, Whirlpool, and More -- Barrons.com

24 feb 2026, 17:02 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Hims & Hers, Keysight, Novo Nordisk, IBM, Kratos, Vir Biotechnology, and More -- Barrons.com

24 feb 2026, 15:09 UTC

Ganancias

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24 feb 2026, 12:44 UTC

Ganancias

These Stocks Are Today's Movers: AMD, Home Depot, Novo Nordisk, Hims & Hers, Keysight, Vir Biotechnology, and More -- Barrons.com

24 feb 2026, 12:06 UTC

Ganancias

These Stocks Are Today's Movers: Home Depot, Novo Nordisk, Hims & Hers, IBM, BWX, Kratos, Vir, and More -- Barrons.com

24 feb 2026, 11:59 UTC

Ganancias

These Stocks Are Today's Movers: Home Depot, Novo Nordisk, Hims & Hers, IBM, BWX, Kratos, Vir, and More -- Barrons.com

24 feb 2026, 11:59 UTC

Ganancias

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24 feb 2026, 10:29 UTC

Ganancias

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. -- Barrons.com

24 feb 2026, 10:15 UTC

Acciones populares

Stocks to Watch Tuesday: FedEx, Home Depot, Apple -- WSJ

23 feb 2026, 21:53 UTC

Ganancias

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23 feb 2026, 21:25 UTC

Ganancias

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

19 feb 2026, 19:55 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion Deal -- Barrons.com

19 feb 2026, 15:06 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion Deal -- Barrons.com

19 feb 2026, 14:19 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion Deal -- Barrons.com

19 feb 2026, 12:25 UTC

Adquisiciones, fusiones, absorciones

Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider -- Barrons.com

11 feb 2026, 10:12 UTC

Charlas de Mercado

Novo Nordisk Can Still Regain Grasp on Obesity Opportunity -- Market Talk

10 feb 2026, 21:51 UTC

Ganancias

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:17 UTC

Ganancias

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

9 feb 2026, 15:07 UTC

Acciones populares

Stocks to Watch Monday: Novo Nordisk, Hims & Hers, Apollo -- WSJ

6 feb 2026, 21:13 UTC

Ganancias

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S (Class B) Esperado

Precio Objetivo

By TipRanks

9.53% repunte

Estimación a 12 meses

Media 1,162.73 DKK 9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.